NASDAQ:CRSP CRISPR Therapeutics - CRSP Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding CRISPR Therapeutics AG Please log in to your account or sign up in order to add this asset to your watchlist. $43.43 +0.29 (+0.67%) (As of 03/24/2023 12:00 AM ET) Add Compare Share Share Today's Range$42.00▼$43.8650-Day Range$43.14▼$56.1252-Week Range$38.94▼$86.95Volume890,032 shsAverage Volume992,671 shsMarket Capitalization$3.42 billionP/E RatioN/ADividend YieldN/APrice Target$72.89 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media CRISPR Therapeutics MarketRank™ ForecastAnalyst RatingHold2.44 Rating ScoreUpside/Downside67.8% Upside$72.89 Price TargetShort InterestBearish14.81% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.47Based on 10 Articles This WeekInsider TradingSelling Shares$3.52 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($7.54) to ($5.28) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.10 out of 5 starsMedical Sector506th out of 1,005 stocksBiological Products, Except Diagnostic Industry90th out of 168 stocks 4.2 Analyst's Opinion Consensus RatingCRISPR Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.44, and is based on 9 buy ratings, 8 hold ratings, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $72.89, CRISPR Therapeutics has a forecasted upside of 67.8% from its current price of $43.43.Amount of Analyst CoverageCRISPR Therapeutics has been the subject of 10 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 0.0 Short Interest Percentage of Shares Shorted14.81% of the float of CRISPR Therapeutics has been sold short.Short Interest Ratio / Days to CoverCRISPR Therapeutics has a short interest ratio ("days to cover") of 10, which indicates bearish sentiment.Change versus previous monthShort interest in CRISPR Therapeutics has recently increased by 8.98%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldCRISPR Therapeutics does not currently pay a dividend.Dividend GrowthCRISPR Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CRSP. Previous Next 2.5 News and Social Media Coverage News SentimentCRISPR Therapeutics has a news sentiment score of 0.47. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.70 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 10 news articles for CRISPR Therapeutics this week, compared to 3 articles on an average week.Search Interest68 people have searched for CRSP on MarketBeat in the last 30 days. This is an increase of 1% compared to the previous 30 days.MarketBeat FollowsOnly 24 people have added CRISPR Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -4% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, CRISPR Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $3,516,250.00 in company stock.Percentage Held by InsidersOnly 5.30% of the stock of CRISPR Therapeutics is held by insiders.Percentage Held by Institutions71.51% of the stock of CRISPR Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for CRISPR Therapeutics are expected to grow in the coming year, from ($7.54) to ($5.28) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of CRISPR Therapeutics is -5.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of CRISPR Therapeutics is -5.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCRISPR Therapeutics has a P/B Ratio of 1.81. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About CRISPR Therapeutics (NASDAQ:CRSP) StockCRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.Read More Receive CRSP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for CRISPR Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address CRSP Stock News HeadlinesMarch 24, 2023 | americanbankingnews.comCRISPR Therapeutics AG (NASDAQ:CRSP) Receives Average Rating of "Hold" from AnalystsMarch 23, 2023 | americanbankingnews.comCRISPR Therapeutics (NASDAQ:CRSP) Now Covered by Sanford C. BernsteinMarch 25, 2023 | Behind the Markets (Ad)Buy THIS stock before Taiwan is attacked... If the United States goes to war with another nuclear armed superpower, this could have a devastating impact on your retirement portfolio. Now, even Taiwan's own foreign minister is saying that China is on the cusp of a full scale invasion. But the good news is, if China invades Taiwan, there is a way to protect yourself.March 22, 2023 | finance.yahoo.comIntellia's (NTLA) HAE Therapy Granted RMAT by the FDAMarch 20, 2023 | americanbankingnews.comBryan, Garnier & Co Begins Coverage on CRISPR Therapeutics (NASDAQ:CRSP)March 20, 2023 | americanbankingnews.comCitigroup Cuts CRISPR Therapeutics (NASDAQ:CRSP) Price Target to $55.00March 17, 2023 | americanbankingnews.comCRISPR Therapeutics AG (NASDAQ:CRSP) Short Interest UpdateMarch 14, 2023 | finance.yahoo.comCRISPR Therapeutics to Present at the American Association for Cancer Research 2023 Annual MeetingMarch 25, 2023 | Stansberry Research (Ad)The gold catalyst we’ve waited forIf you thought the SVB meltdown was bad… watch out. Because even bigger red flag just appeared. This signal proves that a recession is likely right around the corner. It will take most by surprise. Stocks will crash. Millions will go jobless, and lose their homes. But there is ONE important step you should take today to make sure you come out the other side OK. March 14, 2023 | finanznachrichten.deCRISPR Therapeutics AG: CRISPR Therapeutics Announces Transition of Chief Financial OfficerMarch 13, 2023 | msn.comRaju Prasad named next CFO of CRISPR TherapeuticsMarch 11, 2023 | uk.finance.yahoo.comGrowth stocks in focus: can buying CRISPR Therapeutics at $50 make me rich?March 10, 2023 | finance.yahoo.comAstraZeneca (AZN) Posts Positive Data From Lung Cancer StudiesMarch 10, 2023 | finance.yahoo.comNeoleukin (NLTX) Up 36% on Initiating Another Restructuring PlanMarch 4, 2023 | morningstar.comCRISPR Therapeutics’ Pipeline Continues to Make ProgressFebruary 27, 2023 | finance.yahoo.comCRISPR Therapeutics to Participate in the 43rd Annual Cowen Health Care ConferenceFebruary 24, 2023 | finance.yahoo.comHas CRISPR Therapeutics (CRSP) Outpaced Other Medical Stocks This Year?February 22, 2023 | benzinga.comLooking Into CRISPR Therapeutics's Return On Invested CapitalFebruary 22, 2023 | finance.yahoo.comCrispr Therapeutics: FDA Filing on Sickle Cell Gene Therapy Is Almost DoneFebruary 18, 2023 | finance.yahoo.com2 Marvelous Growth Stocks to Buy Today and Hold for 5 Years or LongerFebruary 7, 2023 | bizjournals.comVertex has built a CF empire. Next up: cell and gene therapy.February 6, 2023 | finance.yahoo.comReady to Buy the Dip? Consider This Gene Editing StockFebruary 2, 2023 | msn.com3 CRISPR Stocks to Buy Now Or You’ll Be Kicking Yourself LaterFebruary 1, 2023 | msn.comJim Cramer Says This Is 'One Of Those Crazy Science Stocks That In This Market Will Work Perfectly'January 20, 2023 | finance.yahoo.comA Look At The Fair Value Of CRISPR Therapeutics AG (NASDAQ:CRSP)January 18, 2023 | markets.businessinsider.com3 CRISPR Stocks That Will Make You Filthy Rich in 10 YearsJanuary 13, 2023 | seekingalpha.comPrime Medicine 'Crispr 3.0' Vs. Crispr TherapeuticsSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive CRSP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for CRISPR Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address CRSP Company Calendar Last Earnings2/21/2023Today3/25/2023Next Earnings (Estimated)5/08/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CRSP CUSIPN/A CIK1674416 Webwww.crisprtx.com Phone(141) 561-3277FaxN/AEmployees473Year FoundedN/APrice Target and Rating Average Stock Price Forecast$72.89 High Stock Price Forecast$123.00 Low Stock Price Forecast$39.00 Forecasted Upside/Downside+67.8%Consensus RatingHold Rating Score (0-4)2.44 Research Coverage18 Analysts Profitability EPS (Most Recent Fiscal Year)($8.37) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-650,170,000.00 Net Margins-54,271.70% Pretax Margin-54,298.84% Return on Equity-31.85% Return on Assets-26.91% Debt Debt-to-Equity RatioN/A Current Ratio15.30 Quick Ratio15.30 Sales & Book Value Annual Sales$1.20 million Price / Sales2,846.47 Cash FlowN/A Price / Cash FlowN/A Book Value$23.95 per share Price / Book1.81Miscellaneous Outstanding Shares78,650,000Free Float74,479,000Market Cap$3.42 billion OptionableOptionable Beta1.73 Key ExecutivesDr. Rodger Novak M.D. (Age 55)Founder, Chairman & Pres Dr. Samarth Kulkarni (Age 43)CEO & Director Comp: $1.18MDr. Lawrence Otto Klein Ph.D. (Age 40)Chief Operating Officer Comp: $675kMr. James R. Kasinger (Age 50)Gen. Counsel & Sec. Comp: $648.93kMr. Shaun FoyFounderDr. Emmanuelle Marie CharpentierCo-Founder & Scientific Advisory Board MemberDr. Craig C. Mello Ph.D.Scientific Founder & Advisory Board MemberDr. Chad Cowan Ph.D.Scientific FounderDr. Matthew Porteus M.D. (Age 56)Ph.D., Scientific Founder & Advisory Board Member Dr. Daniel G. Anderson Ph.D.Scientific Founder & Advisory Board MemberMore ExecutivesKey CompetitorsDenali TherapeuticsNASDAQ:DNLIAbcamNASDAQ:ABCMVir BiotechnologyNASDAQ:VIRVaxcyteNASDAQ:PCVXGinkgo BioworksNYSE:DNAView All CompetitorsInsiders & InstitutionsB. Riley Wealth Advisors Inc.Sold 1,414 shares on 3/15/2023Ownership: 0.008%Rockefeller Capital Management L.P.Sold 14,666 shares on 3/6/2023Ownership: 0.103%Oliver Lagore Vanvalin Investment GroupSold 1,050 shares on 3/2/2023Ownership: 0.001%Voya Investment Management LLCBought 269 shares on 2/28/2023Ownership: 0.028%Samarth KulkarniSold 25,000 sharesTotal: $1.21 M ($48.25/share)View All Insider TransactionsView All Institutional Transactions CRSP Stock - Frequently Asked Questions Should I buy or sell CRISPR Therapeutics stock right now? 18 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for CRISPR Therapeutics in the last year. There are currently 1 sell rating, 8 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" CRSP shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CRSP, but not buy additional shares or sell existing shares. View CRSP analyst ratings or view top-rated stocks. What is CRISPR Therapeutics' stock price forecast for 2023? 18 equities research analysts have issued 1 year price targets for CRISPR Therapeutics' stock. Their CRSP share price forecasts range from $39.00 to $123.00. On average, they predict the company's share price to reach $72.89 in the next twelve months. This suggests a possible upside of 67.8% from the stock's current price. View analysts price targets for CRSP or view top-rated stocks among Wall Street analysts. How have CRSP shares performed in 2023? CRISPR Therapeutics' stock was trading at $40.65 at the start of the year. Since then, CRSP shares have increased by 6.8% and is now trading at $43.43. View the best growth stocks for 2023 here. When is CRISPR Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 8th 2023. View our CRSP earnings forecast. How were CRISPR Therapeutics' earnings last quarter? CRISPR Therapeutics AG (NASDAQ:CRSP) issued its earnings results on Tuesday, February, 21st. The company reported ($1.41) earnings per share for the quarter, topping the consensus estimate of ($2.27) by $0.86. The firm earned $6 million during the quarter, compared to analysts' expectations of $7.37 million. CRISPR Therapeutics had a negative trailing twelve-month return on equity of 31.85% and a negative net margin of 54,271.70%. CRISPR Therapeutics's quarterly revenue was down 53.5% on a year-over-year basis. During the same period in the prior year, the firm posted ($1.84) EPS. What ETFs hold CRISPR Therapeutics' stock? ETFs with the largest weight of CRISPR Therapeutics (NASDAQ:CRSP) stock in their portfolio include Kelly CRISPR & Gene Editing Technology ETF (XDNA), ARK Genomic Revolution ETF (ARKG), Loncar Cancer Immunotherapy ETF (CNCR), Global X Genomics & Biotechnology ETF (GNOM), iShares Genomics Immunology and Healthcare ETF (IDNA), ARK Innovation ETF (ARKK), AXS Green Alpha ETF (NXTE) and Jacob Forward ETF (JFWD). What other stocks do shareholders of CRISPR Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other CRISPR Therapeutics investors own include NVIDIA (NVDA), Editas Medicine (EDIT), Alibaba Group (BABA), Micron Technology (MU), Advanced Micro Devices (AMD), Block (SQ), Tesla (TSLA), Intellia Therapeutics (NTLA), QUALCOMM (QCOM) and Shopify (SHOP). When did CRISPR Therapeutics IPO? (CRSP) raised $75 million in an initial public offering (IPO) on Wednesday, October 19th 2016. The company issued 4,700,000 shares at $15.00-$17.00 per share. Citigroup, Piper Jaffray and Barclays served as the underwriters for the IPO and Guggenheim Securities was co-manager. What is CRISPR Therapeutics' stock symbol? CRISPR Therapeutics trades on the NASDAQ under the ticker symbol "CRSP." Who are CRISPR Therapeutics' major shareholders? CRISPR Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include ARK Investment Management LLC (10.00%), Sumitomo Mitsui Trust Holdings Inc. (5.12%), Nikko Asset Management Americas Inc. (5.12%), T. Rowe Price Investment Management Inc. (3.82%), NEA Management Company LLC (2.03%) and Price T Rowe Associates Inc. MD (1.43%). Insiders that own company stock include Bradley J Phd Bolzon, Bradley J Phd Bolzon, James R Kasinger, Lawrence Otto Klein, Michael John Tomsicek, Rodger Novak, Samarth Kulkarni, Tony W Ho and Tony W Ho. View institutional ownership trends. How do I buy shares of CRISPR Therapeutics? Shares of CRSP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is CRISPR Therapeutics' stock price today? One share of CRSP stock can currently be purchased for approximately $43.43. How much money does CRISPR Therapeutics make? CRISPR Therapeutics (NASDAQ:CRSP) has a market capitalization of $3.42 billion and generates $1.20 million in revenue each year. The company earns $-650,170,000.00 in net income (profit) each year or ($8.37) on an earnings per share basis. How many employees does CRISPR Therapeutics have? The company employs 473 workers across the globe. How can I contact CRISPR Therapeutics? CRISPR Therapeutics' mailing address is BAARERSTRASSE 14, ZUG V8, CH-6300. The official website for the company is www.crisprtx.com. The company can be reached via phone at (141) 561-3277 or via email at susan.kim@crisprtx.com. This page (NASDAQ:CRSP) was last updated on 3/25/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.